TY  - JOUR
AU  - Hernandez-Agudo, Elena
AU  - Mondejar, Tamara
AU  - Soto-Montenegro, Maria Luisa
AU  - Megias Vazquez, Diego
AU  - Mouron, Silvana Andrea
AU  - Sanchez, Jesus
AU  - Hidalgo, Manuel
AU  - Lopez-Casas, Pedro Pablo
AU  - Mulero Francisca, Francisca
AU  - Desco, Manuel
AU  - Quintela Fandino, Miguel Angel
PY  - 2016
DO  - 10.1016/j.molonc.2015.12.011
SN  - 15747891
UR  - http://hdl.handle.net/20.500.12105/8537
AB  - BACKGROUND: Rationalization of antiangiogenics requires biomarkers. Vascular re-normalization is one widely accepted mechanism of action for this drug class. The interstitium of tumors with abnormal vasculature is hypoxic. We sought to track vascular...
LA  - eng
PB  - Wiley
KW  - (18)F-misonidazole-PET
KW  - Antiangiogenics
KW  - Biomarker
KW  - Breast cancer
KW  - Pancreatic cancer
KW  - Vascular normalization
KW  - Angiogenesis Inhibitors
KW  - Animals
KW  - Antimetabolites, Antineoplastic
KW  - Benzimidazoles
KW  - Breast
KW  - Breast Neoplasms
KW  - Cell Hypoxia
KW  - Cell Line, Tumor
KW  - Deoxycytidine
KW  - Female
KW  - Fluorine Radioisotopes
KW  - Humans
KW  - Mice
KW  - Mice, Nude
KW  - Misonidazole
KW  - Neovascularization, Pathologic
KW  - Pancreas
KW  - Pancreatic Neoplasms
KW  - Positron-Emission Tomography
KW  - Quinolones
TI  - Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET
TY  - journal article
ER  -